Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. We are seeking an experienced Director of Screening Platform Technology to lead a multidisciplinary team responsible for the design, execution, and evolution of Revolution Medicines’ screening platforms. This role will oversee assay operations, new process implementation, and screening analytics and controls, and will partner closely with software engineers, automation engineers, and a cross-functional screening strategy taskforce. The successful candidate will bring strong people leadership, deep experience in high-throughput screening platforms, and direct technical expertise in screening analytics and data-driven experimental design.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree